MedTrace Logo

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

NCT02137707 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2018-11-09

No results posted yet for this study

Summary

This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.

Conditions

  • Multiple Sclerosis-Relapsing-Remitting

Interventions

DRUG

Gilenya

All patients will receive Gilenya

Sponsors & Collaborators

Principal Investigators

  • Jack Antel, MD · McGill University

  • Amit Bar-Or, MD · McGill University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-11-30
Completion
2018-10-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137707 on ClinicalTrials.gov